BiotechTube

ANAVEX2-73 + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rett Syndrome

Conditions

Rett Syndrome

Trial Timeline

May 6, 2019 → Sep 30, 2021

NCT ID
NCT03941444

About ANAVEX2-73 + Placebo

ANAVEX2-73 + Placebo is a phase 3 stage product being developed by Anavex Life Sciences for Rett Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03941444. Target conditions include Rett Syndrome.

What happened to similar drugs?

3 of 8 similar drugs in Rett Syndrome were approved

Approved (3) Terminated (3) Active (2)
✅Esomeprazole + Aspirin + RofecoxibAstraZenecaApproved
✅Esomeprazole + LansoprazoleAstraZenecaApproved
✅Esomeprazole MagnesiumAstraZenecaApproved
❌GWP42003-P + PlaceboJazz PharmaceuticalsPhase 3
❌GWP42003-PJazz PharmaceuticalsPhase 3
❌trofinetideAcadia PharmaceuticalsPhase 3
🔄TrofinetideAcadia PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03941444Phase 3Completed
NCT03758924Phase 2Completed

Competing Products

20 competing products in Rett Syndrome

See all competitors
ProductCompanyStageHype Score
Esomeprazole + Aspirin + RofecoxibAstraZenecaApproved
43
Esomeprazole + LansoprazoleAstraZenecaApproved
43
Esomeprazole MagnesiumAstraZenecaApproved
43
AZD5213 and placeboAstraZenecaPhase 2
35
fingolimod (FTY720)NovartisPhase 1/2
32
PF-03654746 + Placebo + Placebo + PF-03654746PfizerPhase 2
27
AripiprazoleBristol Myers SquibbPre-clinical
18
NBI-98854Neurocrine BiosciencesPhase 2
24
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
24
ValbenazineNeurocrine BiosciencesPhase 2
32
NBI-98854Neurocrine BiosciencesPhase 1
26
Valbenazine + Placebo oral capsuleNeurocrine BiosciencesPhase 2
32
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
32
ValbenazineNeurocrine BiosciencesPhase 2
32
NBI-98854 + PlaceboNeurocrine BiosciencesPhase 2
32
Abobotulinum toxin AIpsenPre-clinical
19
GWP42003-P + PlaceboJazz PharmaceuticalsPhase 3
29
GWP42003-PJazz PharmaceuticalsPhase 3
29
trofinetideAcadia PharmaceuticalsPhase 3
29
TrofinetideAcadia PharmaceuticalsPhase 3
37